| CME Provider |
Website title |
Module | CME
credits |
Expiry |
|
Academic Medical Center Amsterdam. Dept Vascular Medicine |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
HbA1c in CVD |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
Hypoglycemia in CV medicine - why worry? |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
Key classes of antidiabetic drugs |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
Natural history of diabetes: focus on microvascular and macrovascular complications |
1 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc |
T2DM and CV outcomes |
0 |
04 Jun 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Managing Diabetes & CVD: Is epigenetics a new way forward? - https://academy1745879297.coursepath.com/my-courses |
Insights from the first trials in epigenetics in human: What is the way forward? |
1 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Managing Diabetes & CVD: Is epigenetics a new way forward? - https://academy1745879297.coursepath.com/my-courses |
Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do? |
1 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Managing Diabetes & CVD: Is epigenetics a new way forward? - https://academy1745879297.coursepath.com/my-courses |
Promise of epigenetic modulation as a target in atherosclerotic patients. |
1 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure - https://academy1745879297.coursepath.com/my-courses |
Heart failure & Diabetes: Time for a more unified approach |
1 |
09 Dec 2019 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure - https://academy1745879297.coursepath.com/my-courses |
Management of CV Risk & T2DM: Implications of novel outcome trials |
1 |
09 Dec 2019 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure - https://academy1745879297.coursepath.com/my-courses |
SGLT2 inhibition in cardiology: What a cardiologist needs to know |
1 |
09 Dec 2019 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies - https://academy1745879297.coursepath.com/my-courses |
PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials |
1 |
25 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies - https://academy1745879297.coursepath.com/my-courses |
PCSK9 inhibition across a wide spectrum of patients: For whom is it efficacious? |
1 |
25 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies - https://academy1745879297.coursepath.com/my-courses |
Understanding new PCSK9 outcome data: From the LDL |
1 |
25 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Diagnosis, classification of patients, prognosis |
0 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Future perspectives |
0 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Treatment options, follow-up of non-responsive patients, optimization of therapy |
0 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc |
Underlying pathophysiology, characteristics, clinical subgroups, prevalence and risk factors |
1 |
23 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? - https://academy1745879297.coursepath.com/my-courses |
Challenging CV risk in diabetes: Ready for a new approach? |
0 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? - https://academy1745879297.coursepath.com/my-courses |
Heart failure & diabetes: SGLT2 inhibition, a paradigm shift? |
0 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? - https://academy1745879297.coursepath.com/my-courses |
SGLT-2 inhibitors in T2DM Management: Current position & future promise |
0 |
24 Jan 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
Inflammation & CVD: Translating insights from vascular biology to the clinic |
0 |
07 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
The CANTOS trial: Implications for the management of patients with residual risk |
0 |
07 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
The new era of residual risk reduction |
0 |
07 May 2020 |
| Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein |
Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc |
The patient with inflammatory residual risk: Who is it? |
1 |
07 May 2020 |
|
Faculte de Medecine Pierre et Marie Curie |
| Faculte de Medecine Pierre et Marie Curie/ A. Carrie |
e-learning on genetic testing in FH - http://elearning.cor2ed.com/ |
Genetic testing and diagnosis of FH |
1 |
10 Jan 2019 |
|
Heart Failure Association of the ESC |
| Heart Failure Association of the ESC/ A. Mebazaa |
Acute heart failure: diagnosis - http://learn.escardio.org/Default.aspx |
Acute heart failure: diagnosis |
1 |
29 Jun 2018 |
| Heart Failure Association of the ESC/ TA. Mcdonagh |
Disease management programme in HF - http://learn.escardio.org/Default.aspx |
Disease management programme in HF |
2 |
29 Jun 2018 |
| Heart Failure Association of the ESC/ S. Von Haehling |
Treating Heart Failure Early - http://learn.escardio.org/Default.aspx |
Treating Heart Failure Early |
1 |
28 Jun 2018 |
|
Maastricht University Medical Center |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
Case study: Successful AF ablation program - perils, pitfalls and tricks |
0 |
17 May 2020 |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
Introduction: What is the value of a multidisciplianry AF Heart Team? |
1 |
17 May 2020 |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
What are the practical considerations for implementing a MDT Heart Team in your hospital? |
0 |
17 May 2020 |
| Maastricht University Medical Center/ H. Crijns |
Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage |
What evidence exists to support hybrid ablation? |
0 |
17 May 2020 |
|
The University of Edinburgh |
| The University of Edinburgh/ K. Fox |
Achieving Long-Term Protection Post-MI: The Accumulated Evidence - http://www.medscape.org/ |
Achieving Long-Term Protection Post-MI: The Accumulated Evidence |
1 |
22 Aug 2018 |
| The University of Edinburgh/ K. Fox |
Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum - http://www.medscape.org/ |
Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum |
1 |
27 Oct 2018 |
| The University of Edinburgh/ K. Fox |
CV Risk Doesn't End in the Cath Lab: Event-Free Survival Is a Lasting Commitment - http://www.medscape.org |
CV Risk Doesn't End in the Cath Lab: Event-Free Survival Is a Lasting Commitment |
1 |
09 Dec 2019 |
| The University of Edinburgh/ K. Fox |
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials - http://www.staging.medscape.org/viewarticle/876882 |
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials |
1 |
28 May 2019 |
| The University of Edinburgh/ K. Fox |
Evidence-Based Antiplatelet Therapy Across the ACS Spectrum: Hospital to Home - http://www.staging.medscape.org/viewarticle/863385 |
Evidence-Based Antiplatelet Therapy Across the ACS Spectrum: Hospital to Home |
1 |
29 Jun 2018 |
| The University of Edinburgh/ K. Fox |
Improving ACS Outcomes: Acute Treatment and Chronic Management - http://www.staging.medscape.org/viewarticle/882603 |
Improving ACS Outcomes: Acute Treatment and Chronic Management |
1 |
22 Aug 2019 |
| The University of Edinburgh/ K. Fox |
Optimal Antiplatelet Therapy in the Patient With PAD: Are We There? - http://www.medscape.org/ |
Optimal Antiplatelet Therapy in the Patient With PAD: Are We There? |
1 |
27 Oct 2018 |
| The University of Edinburgh/ K. Fox |
PAD Patients vs Post-ACS Patients: Insights From Antiplatelet Trials - http://www.staging.medscape.org/viewarticle/873056 |
PAD Patients vs Post-ACS Patients: Insights From Antiplatelet Trials |
1 |
18 Jan 2019 |
|
UpToDate |
| UpToDate/ T. Post |
https://uptodate.com - https://www.uptodate.com |
UpToDate |
1 |
14 Mar 2020 |
